companies / sidewinderbio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-17 json
| total_raised | 90,000,00090.0M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | San Diego | |
| industry | unknown | |
| stage | series-b+ |
Sidewinder Therapeutics develops bispecific antibody-drug conjugates that target receptor co-complexes on solid tumors. It serves patients with difficult-to-treat solid cancers who need better therapeutic options. By binding two receptors at once, its conjugates aim to improve tumor cell internalization and widen the therapeutic window.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-08-10 | series-b | 60,000,00060.0M | null | ○ |
all in one seo 4.9.5.1, all in one seo pack 4.9.5.1, bugherd, cdnjs, cloudflare, cloudflare bot management, doubleclick floodlight, google analytics, google tag manager, gravity forms 2.9.31, http/3, jquery migrate 3.4.1
| fact | status | src |
|---|---|---|
| Series B, $60.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |